Health-related quality of life in children with chronic hepatitis C  by Behairy, Ola Galal Ali
Egyptian Pediatric Association Gazette (2016) 64, 120–125HO ST E D  BY Contents lists available at ScienceDirect
Egyptian Pediatric Association Gazette
journal homepage: http://www.elsevier.com/locate/epagHealth-related quality of life in children with
chronic hepatitis CPeer review under responsibility of Egyptian Pediatric Association
Gazette.
http://dx.doi.org/10.1016/j.epag.2016.08.001
1110-6638  2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Ola Galal Ali BehairyDepartment of Pediatrics, Faculty of Medicine, Benha University, EgyptReceived 20 February 2016; revised 20 May 2016; accepted 7 August 2016
Available online 21 August 2016KEYWORDS
Pegylated interferon;
Children;
Hepatitis C;
Depression;
Quality of lifeAbstract Background: Mood disturbances, including depression, are relatively common in the
hepatitis C virus-infected population and may worsen during hepatitis C treatment, also hepatitis
C virus infection is associated with decreased quality of life (QOL) and neurocognitive dysfunction
in adults, but little is known about its impact on children.
Aim of the study: To assess the health-related quality of life (HRQOL), behavioral/emotional func-
tioning, and cognitive status of children with hepatitis C infection with and without treatment.
Methods: A total of 120 children who were divided into three groups: group 1: 30 chronic hepatitis
C infected children without treatment, group II: 30 chronic hepatitis C infected children under treat-
ment with peg-interferon and ribavirin, group III: Includes 60 normal children matched for age and
sex as a control group were enrolled in this case–control study. We used the Peds QLTM 4.0 generic
score scale to assess the HRQOL based on a child’s self- and parent proxy reports. Also assessment
of childhood depression using ACDS Inventory, Arabic form based on Kovacs Children’s Depres-
sion Inventory was done.
Results: There was a statistical significant difference between studied groups regarding physical,
emotional, social and school functioning parameter of parents’ reports and child opinion of
PEDSQL score, also there was a statistical significant difference between studied groups regarding
depression score as it was significantly higher in group II (hepatitis C infected children under treat-
ment with peg-interferon and ribavirin).
Conclusion: HRQOL and depression scores were significantly increased in children with chronic
hepatitis C however both were higher in children receiving treatment.
 2016 The Egyptian Pediatric Association. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Hepatitis C virus (HCV) infection is a serious health problem
worldwide that establishes a chronic infection in up to 85% of
cases.1 Estimates of prevalence range from less than 1.0% innorthern Europe to more than 2.9% in northern Africa.2
Many publications suggest that over 15% of the people in
Egypt are infected. This is ten times greater than in any other
country in the world. The prevalence of HCV varies through-
out the country. The available data suggests that the northern
Nile Delta has the highest prevalence, 28%. The much smal-
ler population of upper Egypt, in the south, has a slightly
lower HCV prevalence,  20%. The two major urban centers,
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6%, respectively.3 Studies of the magnitude of HCV infec-
tion in Egyptian children revealed a prevalence of 3% in upper
Egypt and 9% in lower Egypt.4. The course of HCV infection
in children is generally more benign than that seen in adults,
approximately 30 percent of infected children will develop
symptomatic or progressive disease and be at risk for cirrhosis
and hepatocellular carcinoma later in life. However, there is
emerging evidence that chronic HCV treatment in children
and adolescents can yield virologic results comparable to, or
even better than, those in adults.5 HCV infection is associated
with psychiatric symptoms like depression. Together with
other factors (e.g. the severity of hepatic condition), two lines
of evidence support an association between HCV and depres-
sion. First: patient with psychiatric disorder have higher preva-
lence of HCV infection. Second: patient with chronic hepatitis
may have higher prevalence of psychiatric disorder including
depression.6 Antiviral treatment of HCV with IFN-alpha is
associated with severe neuropsychiatric side effect such as psy-
chosis, depression and neuropsychological dysfunction these
symptoms can lead to poor compliance and the need to
decrease or prematurely stop antiviral therapy.7 Health-
related quality of life (HRQOL) is a concept that relates to
an individual’s perception of health status in relation to the
culture and value systems in which they live, in addition to
their expectations, goals, concerns, and living standards. The
chronic HCV literature is replete with findings of quality of life
(QOL), psychological, and cognitive deficits in treatment-naı¨ve
adults as well as those receiving interferon and ribavirin ther-
apy. However, comparatively less is known about how HCV
and its treatment affect these clinical parameters in children.8
While QOL is emerging as an important endpoint in pediatric
clinical trials of HCV treatments, there is a paucity of data on
other patient-oriented outcomes that are pertinent to child
development and function. The inclusion of patient-oriented
outcomes such as behavioral adaptation, depression, anxiety,
and cognitive functioning in HCV pediatric clinical trials is
important for several reasons. The impact of HCV treatments
on these parameters in children is not presently known and
such information will allow health professionals to better
inform patients and their parents about the range of possible
side effects. Also, identifying the complete range of morbidity
associated with chronic HCV and its treatments may facilitate
the development and implementation of psychotherapeutic or
psychopharmacological interventions aimed at attenuating
morbidity in these children.9
Subjects and methods
This was a prospective case–control study approved by the
ethics committee of Benha University. Patients and their par-
ents were informed of the purpose of the current trial and they
signed informed consent forms before their enrollment. A total
of 120 children, 60 chronic hepatitis C who were selected from
Pediatric Hepatology department, National Liver Institute,
Pediatric Hepatology clinic, Benha University hospitals and
60 healthy children selected from general population (aged
8–17 years) in the period from August 2009 to October 2013.
They were divided into three groups: Group 1: Included 30
chronic hepatitis C infected children without treatment, Group
II: Included 30 chronic hepatitis C infected children in the per-iod between 12 to 24 weeks of starting treatment with peg-
interferon and ribavirin. Group III: Included 60 normal chil-
dren as a control group. Inclusion criteria for group I & II:
Age 618 years, positive anti-HCV antibody, detectable serum
HCV-RNA, liver biopsy showing chronic hepatitis with evi-
dence of fibrosis, compensated liver disease (Child-Pugh Grade
A clinical classification). Exclusion criteria: Other causes of
acute or chronic hepatitis, liver cirrhosis, autoimmune hepati-
tis, positive HbsAg and known hypersensitivity to peg-IFN
and ribavirin.
Methodology
Files of the patients were examined and the following data
were retrieved: history, clinical examination, abdominal ultra-
sonography, result of liver needle biopsy, Viral markers (HCV
Ab and HbsAg), complete blood picture (CBC), liver function
tests: [ALT, AST and serum bilirubin (total and direct)] and
serum creatinine. Psychological and behavioral assessment
was done by the current HRQOL questionnaire in pediatrics
that was designed by the World Health Organization (WHO)
and consisted of the 23-item HRQOL generic core scales for
children and teens aged 2 to 18 years old.10 An Arabic trans-
lated questionnaire was used based on The Peds QLTM 4.0
generic core scale which is a 23-item questionnaire of self
and proxy reports consisting of 4 scales to evaluate physical,
emotional, social, and academic functioning.11 A 5-point
response scale ranges from 0 (never a problem) to 4 (almost
always a problem). All questions are addressed twice, once
for patients and once for parents, our participants were aged
between 8 and 17 years and if the child or teen was unable
to complete the self-report forms, the study administrator read
a questionnaire aloud for them and avoided suggesting a speci-
fic answer by avoiding intonation change. Parents self-
administered the PedsQLTM 4.0 after a brief instruction from
the administrator. Assessment of childhood depression for our
patients using ACDS Inventory, Arabic form12 based on
Kovacs Children’s Depression Inventory.13 The Children’s
Depression Inventory (CDI) was completed by the child and
it assessed cognitive and behavioral symptoms of depression.
A total score P12 is indicative of possible clinical depression.
Statistical analysis
Data were tabulated, coded then analyzed using the computer
program SPSS (statistical package for social science) version
16. Quantitative data were presented as mean ± SD. Student’s
t-test was used to compare between two groups. Pearson’s cor-
relation coefficient was used to test correlation between vari-
ables and chi-square test was used to compare frequency of
qualitative variables among the different groups. For all anal-
yses, the level of significance was set at p< 0.05.
Results
This study included a total of 120 subjects; group I: 30 patients
with chronic hepatitis C without treatment [18 males (60%)
and 12 females (40%)], group II: 30 patients with chronic hep-
atitis C treated with peg-interferon and ribavirin [15 males
(50%) and 15 females (50%)] and group III: 60 subjects were
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females (61.7%)]. There was no statistical significant difference
between studied groups regarding sex and age (Table 1). There
was a statistical significant difference between studied groups
regarding physical and emotional parameter of parents’
reports of PEDSQL score as they were higher in HCV treated
cases (group II) (Mean = 18.03 ± 4.62) & (Mean = 14.67
± 2.51) respectively (Table 2). There was a statistical signifi-
cant difference between studied groups regarding physical
and emotional parameter of a child’s opinion of PEDSQL
score as they were higher in HCV treated cases (group II)
(Mean = 15.0 ± 3.38) & (Mean = 14.6 ± 4.73) respectively
(Table 3). There was a statistical significant difference between
studied groups regarding social and school functioning param-
eters of parents’ report of PEDSQL score as they were higher
in HCV treated cases (group II) (Mean = 13.13 ± 2.8) &
(Mean = 11.27 ± 2.08) respectively (Table 4). There was a
statistical significant difference between studied groups regard-
ing school functioning parameter of a child’s opinion of
PEDSQL score as it was higher in HCV treated cases (group
II) (Mean = 11.3 ± 2.6). There was also a statistical signifi-
cant difference between groups I & III, group II & III regard-
ing social parameter of a child’s opinion of PEDSQL score as
it was higher in HCV treated cases (group II) (Mean = 10.47
± 2.85), however there was no statistical significant difference
between group I & group II regarding social parameter of a
child’s opinion of PEDSQL score (Table 5). There was a statis-Table 1 Description and comparison between studied groups regar
Variable Group I (30) Group II (30) Gr
Age Mean ± SD 13.03 ± 2.53 13.33 ± 2.4 12.
Range (8–17) (8–17) (8–
Sex N &% Male 18(60%) 15(50.0) 23(
Female 12(40%) 15(50.0) 37(
Table 2 Description and comparison between studied groups rega
PEDSQL score.
Parent Group I (30) Group II (30) Gro
Physical Mean ± SD 12.93 ± 4.95 18.03 ± 4.62 9.7
Range (3–23) (4–23) (2–
Emotional Mean ± SD 11.67 ± 3.69 14.67 ± 2.51 5.7
Range (0–17) (4–17) (0–
** highly significant.
Table 3 Description and comparison between studied groups rega
PEDSQL score.
Child Group I (30) Group II (30) Gro
Physical Mean ± SD 11.53 ± 5.88 15.0 ± 3.38 8.4
Range (2–22) (2–19) (3–
Emotional Mean ± SD 11.43 ± 6.68 14.6 ± 4.73 4.9
Range (1–13) (1–9) (0–
* significant.
** highly significant.tical significant difference between studied groups regarding
Depression score as it was higher in HCV treated cases (group
II) (Mean = 17.57 ± 5.12) (Table 6).
Discussion
Hepatitis C virus (HCV) infection is one of the major causes of
liver disease in Egypt. Overall prevalence of antibody to HCV
in the general population is around 15–20%.4 In the present
study there was no statistical significant difference between
studied groups regarding sex and age. There was male predom-
inance in both groups 1 and II this is in agreement with The
Egyptian Demographic and Health Survey (EDHS) which evi-
denced that males had a modestly higher infection rate com-
pared to females in areas along the Nile River and evidence
where public shaving of beards and cutting of hair has been
identified as a route of acquiring HCV infection and education
programs may help to reduce transmission in future,14 these
results are also in agreement with those of El Naghi et al.,
who studied the safety and efficacy of Hansenula-derived
PEGylated-interferon alpha-2a and ribavirin combination in
Egyptian children with chronic hepatitis C in Forty-six chil-
dren. They were 33 boys and 13 girls, aged between 4 and
19 years (mean 10.32 ± 3.46 years).15 In the current study
there was a statistical significant difference between studied
groups regarding physical, emotional and school functioning
parameters in both parents’ and child’s opinions of PEDSQLding personal data (sex, age).
oup III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
62 ± 2.5 0.639 0.46 0.198
17)
38.3) 0.114 0.052 0.29
61.7)
rding physical and emotional parameters of parents’ report of
up III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
7 ± 3.1 0.001** 0.001** 0.001**
16)
5 ± 2.73 0.001** 0.001** 0.001**
11)
rding physical and emotional parameter of a child’s opinion of
up III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
7 ± 3.06 0.007** 0.002** 0.001**
15)
7 ± 2.36 0.038* 0.001** 0.001**
11)
Table 4 Description and comparison between studied groups regarding social and school functioning parameters of parents’ report of
PEDSQL score.
Parent Group I (30) Group II (30) Group III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
Social Mean ± SD 10.57 ± 3.8 13.13 ± 2.8 4.57 ± 2.76 0.004** 0.001** 0.001**
Range (0–16) (0–15) (0–10)
SchoolFunctioning Mean ± SD 9.53 ± 4.25 11.27 ± 2.08 6.5 ± 3.19 0.049* 0.001** 0.001**
Range (1–20) (3–13) (2–14)
* significant.
** highly significant.
Table 5 Description and comparison between studied groups regarding social and school functioning parameter of a child’s opinion
of PEDSQL score.
Child Group I (30) Group II (30) Group III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
Social Mean ± SD 9.1 ± 6.21 10.47 ± 2.85 4.4 ± 2.38 0.278 0.001** 0.001**
Range (0–20) (0–12) (0–10)
SchoolFunctioning Mean ± SD 8.4 ± 3.89 11. 3 ± 2.6 5.98 ± 2.63 0.001** 0.001** 0.001**
Range (1–16) (1–13) (2–12)
** highly significant.
Table 6 Description and comparison between studied groups regarding Depression score.
Child Group I (30) Group II (30) Group III (60) P1 (GI&GII) P2 (GI&GIII) P3 (GII&GIII)
Depression Mean ± SD 13.87 ± 6.54 17.57 ± 5.12 7.65 ± 5.2 0.018* 0.001** 0.001**
Range (1–28) (2–26) (0–20)
* significant.
** highly significant.
Health-related quality of life in children 123score as it was significantly higher in HCV treated cases (group
II), also there was statistical significant difference between
studied groups regarding social parameter of parents’ report
of PEDSQL score as it was significantly higher in HCV treated
cases (group II). There was also a statistical significant differ-
ence between groups I & III and groups II & III regarding
social parameter of a child’s opinion of PEDSQL score.
Nydegger et al., reported that in a small group of children
who acquired HCV in the first year of life had lower QOL
compared to non-infected children.16 Iorio et al., examined
QOL in children undergoing treatment for chronic HBV and
HCV infection, they showed that while tolerability was not a
limiting factor in interferon-alpha treatment in children,
QOL deteriorated significantly during treatment and did not
return to baseline until approximately three months after stop-
ping treatment. They noted three- to four-fold increases in irri-
tability and all the psychosocial dimensions of the Sickness
Impact Profile (e.g. Social Interaction, Emotional Behavior,
and Alertness Behavior) during treatment. They suggest that
significant QOL morbidity may accompany interferon-alpha
treatment in children as it does in adults.17. Rodrigue et al.
assessed the quality of life (QOL), behavioral/emotional func-
tioning, and cognitive status of children undergoing treatment
for hepatitis C virus prior to treatment and at 24 weeks,
48 weeks, 6 months following treatment, and at two annual
follow-up visits. After 24 weeks of treatment, mean physical
QOL scores declined significantly for both groups from base-line to 24 weeks of treatment, although scores remained in
the average range. There was no significant time or group
effects for behavioral/emotional or cognitive functioning.
Three children (5%) in the PEG 2a + RV group and no chil-
dren in the PEG 2a + PL group had a clinically significant
increase in depression symptoms. For those children who
received 48 weeks of treatment, there was no significant time
or group effects on any of the outcome measures. A majority
of children in both the PEG 2a + RV and PEG 2a + PL
groups experienced no clinically significant change in physical
QOL, behavioral adjustment, depression, or cognitive func-
tioning during or after treatment. Therefore, overall QOL
and psychosocial functioning are not deleteriously impacted
by PEG 2a + RV or PL treatment of children with HCV.18
IFN is a potent inducer of pro-inflammatory cytokines.
Cytokines cause a variety of changes in the brain, abnormali-
ties in the hypothalamic-pituitary-axis, neurotransmitter sys-
tems, or other mechanisms that lead to symptoms similar to
major depression (anhedonia, reduced activity, listlessness,
hyperalgesia, altered sleep, altered appetite, and poor mem-
ory).19 Raison et al. determined the impact of chronic exposure
to an innate immune cytokine on human sleep architecture.
They noted that chronic exposure to an innate immune cyto-
kine reduced sleep continuity and depth and induced a sleep
pattern consistent with insomnia and hyper arousal. These
data suggest that innate immune cytokines may provide a
mechanistic link between disorders associated with chronic
124 O.G.A. Behairyinflammation, including medical and/or psychiatric illnesses
and insomnia, which, in turn, is associated with fatigue, motor
slowing, and altered cortisol.20 In the current study there was a
statistical significant difference between studied groups regard-
ing Depression score which was elevated in HCV treated cases
(group II). This is in agreement with Hilsabeck et al.21 and
Fontana et al.22 who stated that Depression was one of the
most common diagnoses in HCV patients. Also these results
agree with those of Poynard et al.23 and Nozaki et al.24 who
stated that the variance in rates of IFN-associated depression
may be due to a multitude of factors including dosage, screen-
ing instruments, co-morbid disease, and predisposition to
depressive episodes. They stated that reported rates actually
underestimate the prevalence of depression if subjects are only
followed for a short period of time. In addition, it appears that
the development of depression in IFN-treated individuals may
be dependent on both duration of treatment and dosage of
IFN, but not on previous personal or family history of depres-
sive disorders. In contrast Forton et al.25, Fontana et al.22 and
Lisa et al.26 found that the prevalence of depressed mood or
depression scores were not different between treated and
untreated patients. Wrona,27 found that the presence of antin-
uclear antibodies was associated with more severe degree of
depression, these results support the hypothesis that HCV dri-
ven cellular immune response, rather than HCV itself, plays an
important role in pathogenesis of depression. In a review by
Menkes and MacDonald, it is suggested that depression during
interferon therapy may be associated with increased catabo-
lism of tryptophan, the precursor of serotonin (5-HT) and
anti-serotonergic effects of interferon have been proposed as
a mechanism in the development of interferon-related depres-
sion and may explain why patient’s symptoms from interferon
therapy can be profoundly improved with Selective serotonin
re-uptake inhibitors (SSRI) type antidepressant.28
Conclusion
Overall HRQOL in children with chronic hepatitis C infection
with and without treatment using the Peds QLTM 4.0 ques-
tionnaire showed decreased physical/emotional functioning,
social and school performance however it was lower in chil-
dren receiving treatment. Assessment of depression by Chil-
dren’s Depression Inventory (CDITM) showed an increase in
depression score in children with and without treatment how-
ever it was higher in children receiving treatment.
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